Furthermore, in a small subset of patients who underwent multiple biopsies, the highest HER2 expression was used for analyses, aligning with the guidelines of the European Society for Medical Oncology for breast cancer, which recommend the use of targeted therapy if HER2 status is positive at least once for patients undergoing multiple biopsies37. The gene discussed is ERBB2; the disease is breast carcinoma.